ID: ALA4518075

Max Phase: Preclinical

Molecular Formula: C21H29N7O4

Molecular Weight: 443.51

Molecule Type: Unknown

Representations

Canonical SMILES:  COC(OC)c1nc(N)ncc1-c1nc2c(c(N3CCOC[C@H]3C)n1)C[C@@H]1COCCN21

Standard InChI:  InChI=1S/C21H29N7O4/c1-12-10-31-6-4-27(12)18-14-8-13-11-32-7-5-28(13)19(14)26-17(25-18)15-9-23-21(22)24-16(15)20(29-2)30-3/h9,12-13,20H,4-8,10-11H2,1-3H3,(H2,22,23,24)/t12-,13-/m1/s1

Standard InChI Key:  UHRJFNHRWLOREP-CHWSQXEVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 443.51

Molecular Weight (Monoisotopic): 443.2281

AlogP: 0.79

#Rotatable Bonds: 5

Polar Surface Area: 120.98

Molecular Species: NEUTRAL

HBA: 11

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 6.73

CX LogP: 2.08

CX LogD: 2.08

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.66

Np Likeness Score: -0.50

References

1. Borsari C, Rageot D, Dall'Asen A, Bohnacker T, Melone A, Sele AM, Jackson E, Langlois JB, Beaufils F, Hebeisen P, Fabbro D, Hillmann P, Wymann MP..  (2019)  A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.,  62  (18): [PMID:31465220] [10.1021/acs.jmedchem.9b00972]

Source

Source(1):

• Scientific Literature